From the Research
Delta sleep-inducing peptide (DSIP) does not have a standardized or typical dose for clinical use because it is not approved by regulatory agencies like the FDA for medical treatment. In research settings, doses have ranged from 25 to 100 micrograms when administered intravenously, with some studies using higher amounts, as seen in studies such as 1 where a dosage of 25 nmol/kg was used. The peptide has been investigated for potential effects on sleep regulation, pain management, and stress reduction, but conclusive evidence for its efficacy and safety is lacking, with some studies showing improvement in sleep patterns, such as 2, while others found little clinical significance, as in 3. DSIP is a naturally occurring neuropeptide consisting of nine amino acids that was initially isolated from the brains of rabbits in sleep-induced states. Despite its name suggesting sleep-promoting properties, clinical evidence supporting its effectiveness for sleep disorders remains insufficient. Key points to consider include:
- Lack of regulatory approval
- Uncertain safety profiles
- Non-standardized production, which creates significant risks for those attempting to use it outside of controlled research environments, as highlighted by the varying results in studies 4, 5. Anyone considering DSIP should be aware of these factors and the potential risks associated with its use. In terms of specific dosing, the most recent and highest quality study, 2, used a dose of 30 nmol/kg, but this is still within the context of experimental research and not clinical practice. Therefore, the use of DSIP should be approached with caution and only considered in the context of controlled research studies.